Slide 1SARQA/DKG Conference 3-4 October 2002 1 SARQA/DKG Conference 3-4 OCTOBER 2002 Annex 13 Update An Industry Perspective Michael J Cooke Director, Global GMP QA AstraZeneca…

Slide 1Kiev, 04/12/2007 Analysis of EU MRP/DCP procedures regarding to generic applications Dr.Raimonds Lozda, FMS Baltic Ltd Slide 2 Kiev, 04/12/2007 EU Authorities National…

Slide 1Advanced Therapy Regulation Hearing, Brussels May 11, 2006 Dr.Andreas Reimann CEO, Mukoviszidose e.V. (German Cystic Fibrosis Association) Vice-Chairman, ACHSE e.V.…

Slide 122nd May 2007 EURS Implementation Group Terms of Reference and Roadmap Slide 2 22nd May 2007 Terms of Reference & Roadmap Context of the Group – Telematics Infrastructure…

Slide 1© WHO – PSM Validations –part 2 Workshop on GMP and Quality Assurance of TB products Kuala Lumpur Malaysia, 21 – 25 February 2005 Maija Hietava M.Sci.Pharm…

Slide 1IRESSA Dr Rose McCormack Personalised Healthcare AstraZeneca A Presentation for the Translational Genomics Meeting Royal College of Physicians, London 15 th January…

Slide 1VTM Virtual Therapeutic Moeity Actual Therapeutic Moeity ATM VMP Virtual Medicinal Product AMP Actual Medicinal Product AMPP Actual Medicinal Product Package VMPP…

Slide 1From POM to P From POM to P Wellard’s NHS training wellards.co.uk 2004 Slide 2 POMs and Ps: legal status of medicines The Medicines Act 1968 controls the supply…

Slide 1Groupings: Several Type IA or IA IN affecting one MA One Type IA or change affecting several MAs from the same MAH Tightening of specification limits (change code…

Slide 1 Sicurezza e segnalazione degli eventi avversi: antibiotici, antinfiammatori, antidolorifici, stati febbrili. Effetto Nocebo del farmaco Achille P. Caputi Direttore…